End-of-day quote
Other stock markets
|
||
- SEK | - |
05-27 | Sweden’s IRLAB Therapeutics Names New CEO | MT |
05-27 | IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 | CI |
Sales 2024 * | 65.65M 6.32M 494M | Sales 2025 * | 138M 13.28M 1.04B | Capitalization | 731M 70.35M 5.5B |
---|---|---|---|---|---|
Net income 2024 * | -111M -10.68M -835M | Net income 2025 * | -27M -2.6M -203M | EV / Sales 2024 * | 11 x |
Net cash position 2024 * | 11.93M 1.15M 89.68M | Net Debt 2025 * | 256M 24.67M 1.93B | EV / Sales 2025 * | 7.15 x |
P/E ratio 2024 * |
-4.58
x | P/E ratio 2025 * |
-3.94
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.48% |
Latest transcript on IRLAB Therapeutics AB
Managers | Title | Age | Since |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 31/12/12 |
Chief Executive Officer | 71 | 05/05/17 | |
Nicholas Waters
FOU | Founder | 62 | 31/12/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 31/12/15 |
Rein Piir
BRD | Director/Board Member | 66 | 31/12/15 |
Chairman | 66 | 31/03/19 |
1st Jan change | Capi. | |
---|---|---|
+43.64% | 754B | |
+39.85% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+8.78% | 298B | |
+12.05% | 217B | |
-1.15% | 216B | |
+0.03% | 163B | |
+6.13% | 164B |